News

Osimertinib which was only licensed in February this year is recommended in draft guidance to treat a particularly aggressive form of lung cancer. Earlier this year, NICE said

The company unveiled new data demonstrating Cosentyx delivers high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis out to four years of treatment. The data shows

Data from the VOYAGE 1 trial showed significantly higher proportions of patients receiving guselkumab achieved cleared/minimal disease compared with patients receiving placebo, as defined by at least a

The combination therapy did not demonstrate an improvement in best corrected visual acuity (BCVA) compared to intravitreal aflibercept injection monotherapy at 12 weeks, the primary endpoint of the

With the court’s ruling, Depomed expects market exclusivity until December 2025 for NUCYNTA ER, NUCYNTA and NUCYNTA oral solution (an unmarketed form of NUCYNTA).  Jim Schoeneck, President and CEO of Depomed,

The pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) is for patients with chronic hepatitis C virus (HCV) genotype 1 who failed treatment with DAAs, including therapy with an

The two companies will contribute their respective expertise to study an exon skipping treatment developed by Sarepta, together with an oral NF-kB inhibition treatment developed by Catabasis in

The company, which has a global workforce of 42,300 in 75 countries, said around 500 of the job cuts would be in Denmark. Majority of job cuts will

Under the terms of the agreement, Genentech will obtain exclusive worldwide rights, except South Korea, to develop and commercialize HM95573. Hanmi will receive an initial upfront payment of